News Releases

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

April 28, 2022

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at The 4th International Workshop on CAR-T 2022

April 6, 2022

Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center

March 30, 2022

Anixa Biosciences to Participate in the 2022 Virtual Growth Conference Hosted by M-Vest, a Division of Maxim Group LLC

March 17, 2022

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine

January 25, 2022

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor

January 24, 2022

Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference

December 16, 2021

Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant

December 7, 2021

Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study

October 26, 2021

Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology

October 6, 2021

Latest News & Events

Nov 17, 2025

Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

Read More...

Nov 12, 2025

Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s

Read More...

Nov 10, 2025

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025

Read More...